ArticleScientific reports2017
Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Regulatory roles and translational potential of the Kruppel-like factor family in liver disease.iLIVER · 2026Review
- Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.Pharmacological reviews · 2026Review
- Shikonin treatment ameliorates lipopolysaccharide-induced acute liver failure in mice via regulating miR-106/MCL1 and miR-34a/SIRT1/TP53 signaling.Archives of medical science : AMS · 2026Article
- Development of a High-Throughput Screening Platform and a Pathogenesis Model forInternational journal of molecular sciences · 2025Article
- Review
- Exploring miR-3148's impact on Krüppel-like factor 6-driven mitophagy and apoptosis in myocardial ischemic injury.CytoJournal · 2025Article
- miRNA‑21 promotes the progression of acute liver failure via the KLF6/autophagy/IL‑23 signaling pathway.Molecular medicine reports · 2024Article
- A universal deep-learning model for zinc finger design enables transcription factor reprogramming.Nature biotechnology · 2023Article
- TCDD dysregulation of lncRNA expression, liver zonation and intercellular communication across the liver lobule.Toxicology and applied pharmacology · 2023Article
- KLF6 alleviates hepatic ischemia-reperfusion injury by inhibiting autophagy.Cell death & disease · 2023Article
- Specificity Proteins (SP) and Krüppel-like Factors (KLF) in Liver Physiology and Pathology.International journal of molecular sciences · 2023Review
- TCDD dysregulation of lncRNA expression, liver zonation and intercellular communication across the liver lobule.bioRxiv : the preprint server for biology · 2023Article
- Kruppel-like factor 2 contributes to blood-spinal cord barrier integrity and functional recovery from spinal cord injury by augmenting autophagic flux.Theranostics · 2023Article
- Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3.Journal of clinical medicine · 2022Article
- Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.Journal of virology · 2022Article
- Autophagy plays a double-edged sword role in liver diseases.Journal of physiology and biochemistry · 2022Review
- A Potential Role for SerpinA3N in Acetaminophen-Induced Hepatotoxicity.Molecular pharmacology · 2021Article
- Autophagy in liver diseases.World journal of hepatology · 2021Review
- Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy.Frontiers in medicine · 2021Article
- Role of promoting inflammation of Krüppel-like factor 6 in acute kidney injury.Renal failure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 6 countries.
Svenja SydorDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Paul MankaDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Jan BestDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Sami JafouiDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Jan-Peter SowaDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Miguel Eugenio ZoubekDepartment of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Virginia Hernandez-GeaBarcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Villarroel 170, 08036, Barcelona, Spain.
Francisco Javier CuberoDepartment of Medicine III, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Julia KälschDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Diana VetterDepartment of Surgery, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Maria Isabel FielDivision of Liver Diseases, Department of Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., New York, NY, 10029, USA.
Yujin HoshidaDivision of Liver Diseases, Department of Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., New York, NY, 10029, USA.ORCID 0000-0001-9430-1426
C Billie BianDivision of Liver Diseases, Department of Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., New York, NY, 10029, USA.
Leonard J NelsonInstitute for Bio Engineering (IBioE), Human Tissue Engineering, Faraday Building, The University of Edinburgh, The King's Buildings, Mayfield Road, Edinburgh, EH9 3JL, Scotland, United Kingdom.ORCID 0000-0002-4197-4843
Han MoshageDepartment of Gastroenterology and Hepatology, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Klaas Nico FaberDepartment of Gastroenterology and Hepatology, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Andreas PaulDepartment of General- and Transplant-Surgery, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Hideo A BabaDepartment of Pathology, University Hospital of Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Guido GerkenDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Scott L FriedmanDivision of Liver Diseases, Department of Medicine and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., New York, NY, 10029, USA.ORCID 0000-0003-1178-6195
Ali CanbayDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Lars P BechmannDepartment of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. lars.bechmann@med.ovgu.de.
Essen University Hospital · DEIcahn School of Medicine at Mount Sinai · USUniversity Medical Center Groningen · NLCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESKing's College London · GBRWTH Aachen University · DEUniversidad Complutense de Madrid · ESUniversity Hospital of Zurich · CHUniversity of Edinburgh · GB
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MThe Role of KLF6 in Hepatic FibrosisR01DK056621 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI FRIEDMAN, SCOTT L. · 2000 to 2019
$6.2MMolecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6MChief Scientist Office ETM/182NIDDK NIH HHS R01 DK056621NIDDK NIH HHS R01 DK099558
Abstract
Krüppel-like factor 6 (KLF6) is a transcription factor and tumor suppressor. We previously identified KLF6 as mediator of hepatocyte glucose and lipid homeostasis. The loss or reduction of KLF6 is linked to the progression of hepatocellular carcinoma, but its contribution to liver regeneration and repair in acute liver injury are lacking so far. Here we explore the role of KLF6 in acute liver injury models in mice, and in patients with acute liver failure (ALF). KLF6 was induced in hepatocytes in ALF, and in both acetaminophen (APAP)- and carbon tetrachloride (CCl
Indexed as
AcetaminophenAcute Lung InjuryAnimalsAutophagyCarbon TetrachlorideCarcinoma, HepatocellularCell Line, TumorCell ProliferationGene Expression RegulationGenes, Tumor SuppressorHepatectomyHepatocytesHep G2 CellsHumansKruppel-Like Factor 6LiverAcetaminophenCarbon TetrachlorideKruppel-Like Factor 6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.